Novel near-point-of-care TB molecular tests: navigating the repercussions of sensitivity tradeoffs.

Authors

E A Kendall

Published in

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. Volume 30. Issue 8. Pages 342-349. Jul 31, 2026.

Abstract

New near-point-of-care, swab-based molecular tests for TB offer substantial operational advantages including improved accessibility and cost. However, early data suggest some loss of sensitivity: in particular, these tests tend to miss the lowest-positive molecular signals, such as 'trace' Xpert MTB/RIF Ultra sputum test results. Recent cohort studies suggest most trace signals represent TB disease, even if not currently confirmable by culture. However, the underdiagnosis arising from reduced sensitivity will be greatest in populations with mild disease, where immediate clinical and transmission risks may be lowest and benefits of expanded access may be greatest. Altered test characteristics may also alter empiric TB treatment practices, with variable effects on over-diagnosis. The improved access and yield offered by near-point-of-care platforms and swab specimens are likely to justify these tradeoffs, more than offsetting detrimental effects on case detection in most contexts. Implementation strategies are proposed to mitigate potential harms.

PMID:
42538628
Bibliographic data and abstract were imported from PubMed on 01 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.